- Home
- PWM vs SABS Comparison
PWM vs SABS Comparison
Compare PWM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- SABS
- Stock Information
- Founded
- PWM 2018
- SABS 2014
- Country
- PWM Hong Kong
- SABS United States
- Employees
- PWM N/A
- SABS N/A
- Industry
- PWM
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- SABS Health Care
- Exchange
- PWM Nasdaq
- SABS Nasdaq
- Market Cap
- PWM 34.6M
- SABS 32.1M
- IPO Year
- PWM 2023
- SABS N/A
- Fundamental
- Price
- PWM $1.73
- SABS $3.53
- Analyst Decision
- PWM
- SABS Strong Buy
- Analyst Count
- PWM 0
- SABS 5
- Target Price
- PWM N/A
- SABS $12.40
- AVG Volume (30 Days)
- PWM 1.1M
- SABS 69.6K
- Earning Date
- PWM 01-24-2025
- SABS 11-06-2024
- Dividend Yield
- PWM N/A
- SABS N/A
- EPS Growth
- PWM N/A
- SABS N/A
- EPS
- PWM N/A
- SABS N/A
- Revenue
- PWM $348,528.00
- SABS $1,512,723.00
- Revenue This Year
- PWM N/A
- SABS N/A
- Revenue Next Year
- PWM N/A
- SABS N/A
- P/E Ratio
- PWM N/A
- SABS N/A
- Revenue Growth
- PWM N/A
- SABS N/A
- 52 Week Low
- PWM $0.67
- SABS $2.16
- 52 Week High
- PWM $2.40
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- PWM 61.42
- SABS 46.39
- Support Level
- PWM $1.37
- SABS $3.50
- Resistance Level
- PWM $1.55
- SABS $4.35
- Average True Range (ATR)
- PWM 0.24
- SABS 0.41
- MACD
- PWM 0.02
- SABS -0.07
- Stochastic Oscillator
- PWM 88.34
- SABS 19.22
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.